AstraZeneca

Despite positive news this week regarding its COVID-19 vaccine, AstraZeneca shares dropped due to concerns about side effects and market competitiveness. The news Monday regarding AstraZeneca (NYSE:AZN)'s trial of coronavirus vaccine AZD1222 seemed to be the type of information that would push a stock's price up, not down. Interim results from the phase 1/2 trial…

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New YorkGENEVA (Reuters) - AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.The British drugmaker has…

Need help? Contact us We've detected unusual activity from your computer network To continue, please click the box below to let us know you're not a robot. Why did this happen? Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review…

Image copyright SEAN ELIAS - OXFORD VACCINE TRIAL Image caption Work began on a vaccine in January Pharmaceutical giant AstraZeneca has agreed to manufacture and distribute a Covid-19 vaccine being developed by the University of Oxford if the treatment proves effective.The company's chief executive, Pascal Soriot, said that "the need for a vaccine to defeat…

Published: April 30, 2020 at 8:30 a.m. ET AstraZeneca CEO says will know by June or July whether the vaccine works British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, England. Getty Images British drug maker AstraZeneca has teamed up with the University of Oxford to develop and manufacture a vaccine for coronavirus, in a move…